Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irinotecan Liposome + 5-FU/LV in Advanced Solid Tumors
NCT05086848Phase 1Completed
- Sponsor
- Hengrui
- Start
- May 2016
- Primary completion
- Jun 2018
- Modality
- Lipid-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of irinotecan liposome in solid tumor, sponsored by Hengrui. Primary endpoints: Adverse Event (AE), Dose Limiting Toxicities at 28 days and 1 more. Started May 2016; status: completed.
02
Drugs
irinotecan liposome
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05086848.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05086848.